Author: CALIWAY BIOPHARMACEUTICALS

Posted Date:

April 13, 2026

Caliway’s Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204’s Demonstrated Efficacy and Safety Gain Further Academic Recognition

CALIWAY BIOPHARMACEUTICALS

April 13, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions

CALIWAY BIOPHARMACEUTICALS

April 2, 2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026

CALIWAY BIOPHARMACEUTICALS

March 19, 2026